Fumi Shima, MD, Ph.D
In Drug Discovery Science Laboratory, we are conducting
research on the development of molecularly targeted cancer
therapeutics targeting the Ras/MAPK signaling pathway,
closely linked to oncogenesis.
ras oncogene product Ras (H-, N-, K-Ras) proteins and their
upstream/downstream signaling molecules play quite essential
roles for survival and maintenance of cancer cells and
tissues. Therefore, substances which prevents their
functions presume to become promising anti-cancer drug
candidates.
We are developing novel anti-cancer drug candidates by
making full use of biochemical/molecular
biological/structural biological methods (in collaboration
with Graduate School of Medicine, and the Japan Synchrotron
Radiation Research Institute), and computer simulations (in
collaboration with the RIKEN Institute of Physical and
Chemical Research). We also aim to create a new category of
drug candidates by elucidating their mechanisms of action at
atomic level.
We welcome researchers and students who eager to gain a wide
range of knowledge, from basic medicine to its applications,
and also in manufacturing products in the pharmaceutical
field by utilizing those knowledge, and further welcome
companies interested in our research. Please contact us and
ask for our assistance.
Main research themes: Shima, Yoshikawa, Makino
- Molecular movies of the enzyme-catalytic reaction of the oncogene product Ras and its application to drug discovery
- Research on the development of novel molecular targeted cancer therapeutics targeting Ras/MAPK signaling
- Molecular design of photo-controllable cancer-driver gene products
- Targeting novel integrin mediated RAC/mTORC2 activation cascade to treat metastasis of undifferentiated soft-tissue sarcomas (MSK team has developed and been characterizing monoclonal antibodies targeting novel integrin’s ligand recognition motif, i-domain, to prevent function of novel integrin. KU will validate mode of action of the antibody at atomic level.)
- To test the anti-tumor efficacy of Ras signaling inhibitors on active-Ras-driven soft-tissues sarcoma with aberrant genetic changes on Ras pathway including RAS genes and their regulators. (MSK team will conduct identification and validation of patient-derived cell lines with active Ras through genetic and genomic analysis of both cells and original patients’ tumors.)
Positions and Employment
- 1998 - 2000
-
JSPS Postdoctoral Research Fellow of Department of Physiology
II, Kobe University School of Medicine, JAPAN
Instructor of Department of Physiology II, Kobe University - 2000 - 2002
-
School of Medicine, JAPAN
Assistant Professor of Department of Molecular and Cellular Biology, Kobe University Graduate School of Medicine, JAPAN - 2002 - 2010
- Member, The Japan Diabetes Society
- 2010 - 2011
- Member, The Japanese Biochemical Society
- 2011 - 2015
- Member, The Japanese Cancer Association
- 2015 - 2016
- Member, The a Biology Society of Japan
- 2016 – till present
- Member, The a Biology Society of Japan
Other Experience and Professional Memberships
- 1991-
- Member, The Japanese Society of Internal Medicine
- 1993-
- Member, The Japan Endocrine Society
- 1993-
- Member, The Japan Diabetes Society
- 1995-
- Member, The Japanese Biochemical Society
- 1995-
- Member, The Japanese Cancer Association
- 1995-
- Member, The a Biology Society of Japan
Honors
- 1998年
- Faculty Award for Excellent research, Kobe University Graduate School of Medicine, JAPAN
- 2011年
- Chikako Tanaka Academic Award, Kobe University Graduate School of Medicine, JAPAN
- 2013年
- Faculty Award for Excellent research, Kobe University Graduate School of Medicine, JAPAN
Courses taught and other services provided to students and the home institution
Undergraduate education
- Gastrointestinal physiology, (2001 to 2018) in the medical department of Kobe Univ.
- Physiology training course: ECG & Spirogram (2001 to 2018) in the medical department of Kobe Univ.
Postgraduate education (in the current principal assignment)
- Science,Technology and Innovation Strategy Project Research (2016 to present)
- Research on Science, Technology and Innovation 1 (2016 to present)
- Project-Based Learning of Entrepreneurship in Science and Technology (2016 to present)
- Presentation Exercises (2016 to present)
- Master's Thesis (2016 to present)
- Introduction to Advanced Medicine (2016 to present)
- Advanced Science and Technology Research (2016 to present)
- Advanced Project Research (2016 to present)
- Advanced Course on Development of Molecular Targeted Drugs and Antibody Drugs (2016 to present)